asthma

News

Sanofi claims EU okay for Dupixent in asthma

Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for the fast-growing biologic.

News

Trial could unlock asthma use for GSK’s Trelegy

GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple of years and has new data that could open up a new market.

News

AZ's Fasenra also works in rare organ damage diseases

AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal organ damage, a mid-stage trial has shown.

News

Mylan launches Advair generic at 70% discount in US

Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug.

News

NICE broadens approval for AstraZeneca’s severe asthma drug

AstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma – broadening its recommendations for the drug’s use and giving

News

FDA approves Sanofi/Regeneron's Dupixent in asthma

The US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the companies attempt to build a blockbuster franchise around the drug.

Sanofi claims EU okay for Dupixent in asthma

Trial could unlock asthma use for GSK’s Trelegy

AZ's Fasenra also works in rare organ damage diseases

Mylan launches Advair generic at 70% discount in US

NICE broadens approval for AstraZeneca’s severe asthma drug

FDA approves Sanofi/Regeneron's Dupixent in asthma

CDMOs: Their crucial role and how to select one, with Sigma ...

How to meet your physicians where they are online

asthma

Editor's Picks